Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


D-24 equivalent

This article was originally published in The Tan Sheet

Executive Summary

Ranbaxy ANDA for loratadine 10 mg/pseudoephedrine sulfate 240 mg approved Sept. 21 for over-the-counter sale. Firm joins Impax Labs in having ANDA clearance for equivalents to Schering-Plough's Claritin D-24 (1"The Tan Sheet" July 19, 2004, In Brief)...

You may also be interested in...

Impax and Leiner

Hayward, Calif. -based drug delivery firm has signed a series of agreements with Leiner for supply and distribution of Claritin equivalents slated for late-summer launch, Impax announces July 12. Products include store brand versions of Reditabs and D-24 (1"The Tan Sheet" June 21, 2004, p. 5). The deal "enables IMPAX to further capitalize on our loratadine product franchise," according to CEO Barry Edwards...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts